-transparent.png){kind=logo}
Acute lymphoblastic transformation of chronic myeloid leukaemia (LT-CML) of 7 consecutive patients was treated according to a remission-induction and maintenance therapy used for de novo acute lymphoblastic leukaemia (ALL). All 7 patients achieved a second chronic phase with a median remission duration of 15 months. Two patients showed an isolated central nervous system (CNS) relapse. This did not occur in the 4 patients, who received prophylactic therapy with intrathecal methotrexate. The second transformation was nonlymphoblastic in nature in 4 out of the 5 patients. A treatment protocol similar to that of a bad risk ALL, including long-term maintenance therapy and CNS-prophylaxis is indicated in lymphoblastic transformation of CML.
T de Witte, and
B de Pauw, and
C Haanen
January 2008,
Acta haematologica,
T de Witte, and
B de Pauw, and
C Haanen
June 1978,
British medical journal,
T de Witte, and
B de Pauw, and
C Haanen
September 1977,
British medical journal,
T de Witte, and
B de Pauw, and
C Haanen
August 1977,
British medical journal,
T de Witte, and
B de Pauw, and
C Haanen
March 2009,
Leukemia research,
T de Witte, and
B de Pauw, and
C Haanen
January 1996,
Hematology (Amsterdam, Netherlands),
T de Witte, and
B de Pauw, and
C Haanen
March 1977,
Lancet (London, England),
T de Witte, and
B de Pauw, and
C Haanen
November 1978,
European journal of cancer,
T de Witte, and
B de Pauw, and
C Haanen
January 1992,
Nouvelle revue francaise d'hematologie,
T de Witte, and
B de Pauw, and
C Haanen
October 1970,
Lancet (London, England),
